New Hainan client, Nanhai Net, Nanguo Metropolis Daily February 26 news (reporter Wang Hongxu intern Yin Tianshu) On February 26, the world's first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine (hereinafter referred to as "13-valent pneumonia vaccine") "Weimin Feibao" Hainan first vaccination ceremony was held at the Hainan Provincial Women's and Children's Medical Center, and a 2-month-old infant was vaccinated with the first dose of 13-valent pneumonia vaccine.
2 months of age baby is given the first dose. Intern Yin Tianshu
"Weimin Feibao" is a 13-valent pneumonia vaccine independently developed by the mainland, that is, two carrier proteins are combined with pneumococcal capsular polysaccharides to reduce the epitope inhibition effect induced by the carrier, and the incidence of adverse reactions is low.
Newborns face many diseases after birth, and vaccination is an important means of protecting them. According to reports, the vaccine needs to be administered 4 times during the period from 6 weeks of age to 6 months of age, starting from 6 weeks of age, completing three doses of vaccination at intervals of two months, and completing another dose of booster immunization from December to 15 months.
The world's first dual-carrier 13-valent pneumococcal polysaccharide conjugate vaccine began vaccination in Hainan. Intern Yin Tianshu
"My big treasure was seriously ill with pneumonia when he was 4 years old and was hospitalized, so he came to get this vaccine when Erbao was more than 2 months old." Ms. Liao, the parent of the baby who received the first double-carrier 13-valent pneumonia vaccine in Hainan, said that she heard the news that the vaccine was on the market, and that it could be vaccinated at the Hainan Provincial Women's and Children's Medical Center on the 26th, so she brought the baby to the hospital.
Ms. Liao said that the price of this vaccine is more suitable, and her baby has a total of 4 injections during this month of age, which is more affordable than other vaccines.
Pneumococcal disease is one of the world's leading public health problems and the number one cause of death in children under 5 years of age. Fu Zhenwang, director of the Immunization Planning Office of the Institute of Infectious Disease Prevention and Control of the Hainan Provincial Center for Disease Control and Prevention, said that pneumococcus is the main cause of bacterial pneumonia in children, it can be transmitted through droplets, direct contact and other channels, and the risk of cross-infection of children in closed areas such as kindergartens and school classrooms will be higher, so children under 5 years old are high-risk and high-incidence groups of invasive pneumonia caused by pneumococcal bacteria.
"The entry and use of this dual-carrier 13-valent pneumonia vaccine will provide parents with more choices." Fu Zhenwang said that this vaccine will further reduce the economic burden of parents to vaccinate their children at their own expense, which is of great significance for protecting children's health and promoting the further improvement of vaccine immunization prevention.